

招商银行全资附属机木 A Wholly Owned Subsidiary Of China Merchants Ban

Zhejiang Jingsheng (300316 CH)

High visibility with backlog covering >80% of revenue in 2022E-23E

Jingsheng's net profit in 2021 / 1Q22 grew 99% YoY / 57% YoY, in line with the Company's pre-announced profit estimate. We see high visibility on the upcoming growth as the backlog (as of Mar) reached RMB22.2bn (solar / semiconductor: 94% / 6%) which is enough to cover >80% of our estimated revenue in 2022E-23E. Besides, during the post-results call, management remained confident that (1) the upgrade of solar wafer equipment will continue, and (2) semiconductor equipment will continue to see breakthrough given the robust demand. We have left our earnings forecast unchanged and maintain our TP of RMB93 (45x 2022E P/E). Maintain **BUY**.

- Results review in 2021 and 1Q22. Net profit in 2021 surged 99% YoY to RMB1.71bn, driven by 56% YoY revenue growth and 3.1ppt YoY gross margin expansion (to 39.7%). The Company maintains a payout ratio of 21%, consistent with the previous three years (20-22%). In 1Q22, net profit grew 57% YoY to RMB442mn, driven by 114% YoY increase in revenue but only partially offset by the lack of one-off gains (RMB117mn in 1Q21, largely VAT rebate). The profit growth is therefore in line with our expectation. Net operating cash outflow was RMB744mn in 1Q22 (vs inflow of RMB37mn in 1Q21) as Jingsheng increased the procurement of key components in view of the upcoming shortage potentially.
- Sustainable solar wafer equipment upgrade. Jingsheng believes that the upgrade of wafer equipment to satisfy large size format (182mm and 210mn) will continue over the coming 2-3 years. In particular, the potential decline of wafer price will potentially result in the phase-out of less profitable small-size wafer production capacities, thereby triggering demand for new furnaces. As at end-Mar, backlog for solar equipment reached RMB20.9bn, up 1.1x YoY and 10% QoQ.
- Robust demand for semiconductor equipment. As at Mar 2022, backlog for semiconductor equipment increased 1.4x YoY (26% QoQ) to RMB1.34bn (6% of total backlog). Since the beginning of this year, the demand for 12-inch equipment has increased dramatically, as some customers started to procure equipment in large batch. Besides, given that Jingsheng already received orders for epitaxy equipment (8-inch), management is confident of winning contracts for epitaxy equipment (12-inch) in future.
- Risks: 1) Weaker-than-expected solar power capacity expansion; 2) lower-than-expected gross margin; (3) risk of semiconductor business expansion.

Earnings Summary

(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue (RMB mn)	3,811	5,961	11,830	14,731	17,546
YoY growth (%)	23	56	98	25	19
Net income (RMB mn)	858	1,712	2,671	3,276	3,908
EPS (RMB)	0.67	1.33	2.08	2.55	3.04
YoY growth (%)	35	99	56	23	19
Consensus EPS (RMB)	N/A	0.00	1.88	2.43	0.00
P/E (x)	65.9	33.1	21.2	17.3	14.5
P/B (x)	10.8	8.3	6.2	4.8	3.7
Yield (%)	0.3	0.6	0.9	1.2	1.4
ROE (%)	17.5	28.4	33.4	31.2	28.9
Net gearing (%)	Net cash				

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price RMB93.00 (Previous TP RMB93.00) Up/Downside +97% Current Price RMB47.30

China Capital Goods

Wayne Fung, CFA (852) 3900 0826 waynefung@cmbi.com.hk

Stock Data

Mkt Cap (RMB mn)	60,850
Avg 3 mths t/o (RMB mn)	548
52w High/Low (RMB)	84.99/35.28
Total Issued Shares (mn)	1,286
Source: Bloomberg	

Shareholding Structure

Shaoxing Shangyu Jingsheng	
Invt. Mgmt. and Consulting	48.32%
QIU Minxiu	2.97%
CAO Jianwei	2.77%

Source: Company data

Share Performance

	Absolute	Relative
1-mth	-20.9%	-15.3%
3-mth	-18.7%	-3.6%
6-mth	-36.9%	-20.6%

Source: Bloomberg

12-mth Price Performance



Source: Bloomberg

Auditor: Pan-China CPA

Related Reports

- Zhejiang Jingsheng (300316 CH, BUY) – Solid growth of solar equipment; SiC gaining traction – 3 Mar 2022
- Zhejiang Jingsheng (300316 CH, BUY) – Mega order intake to boost earnings in 2022E-23E; Raising earnings forecast and TP – 1 Sep 2021
- Zhejiang Jingsheng (300316 CH, BUY) Robust solar capex;
 Earnings & TP revised up – 2 Jul 2021




Figure 1: 2021 results review

(RMB mn)	FY20	FY21	YoY
Revenue	3,811	5,961	<i>56</i> %
Equipment and service	3,276	4,977	52%
Sapphire products	194	389	101%
Others	341	595	75%
COGS	-2,416	-3,593	49%
Gross profit	1,395	2,368	70 %
Opex	-436	-653	50%
Core operating profit	959	1,715	79 %
Impairment losses	-137	-100	-27%
Other expenses and incomes	129	300	131%
Pre-tax profit	992	1,984	100%
Income tax	-140	-256	83%
Minority interest	6	-17	n/a
Net profit	858	1,712	99%
Ratios	FY20	FY21	YoY
Gross profit margin	36.6%	39.7%	3.1ppt
Core operating margin	25.2%	28.8%	3.6ppt
ROE	17.5%	28.4%	10.8ppt
ROA	9.3%	12.5%	3.2ppt


Source: Company data, CMBIGM

Figure 2: Jingsheng's net profit growth



Source: Company data, CMBIGM estimates


Figure 3: Jingsheng's total backlog reached RMB22.2bn (including RMB1.3bn from semiconductor) as at end-Mar 2022



Source: Company data, CMBIGM









Source: CPIA, CMBIGM estimates

Figure 5: Monocrystalline wafer (182mm) price trend




Source: PVInfoLink, CMBIGM

Figure 6: Monocrystalline wafer (210mm) price trend




Source: PVInfoLink, CMBIGM

Figure 7: Jingsheng's forward P/E band



Source: Bloomberg, Company data, CMBIGM estimates

Figure 8: Jingsheng's forward P/B band



Source: Bloomberg, Company data, CMBIGM estimates



Financial Summary

Income statement Cash flow

YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E	YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue	3,811	5,961	11,830	14,731	17,546	PAT	852	1,728	2,698	3,309	3,948
Equipment and service	3,276	4,977	10,451	13,064	15,676	D&A	136	153	184	227	276
Sapphire products	194	389	545	709	815	Change in working capital	(124)	(744)	(1,018)	(1,751)	(763)
Others	341	595	833	959	1,054	Others	90	599	(40)	(44)	(49)
COGS	(2,416)	(3,593)	(7,406)	(9,254)	(10,999)	Operating cash flow	954	1,737	1,824	1,740	3,411
Gross profit	1,395	2,368	4,423	5,477	6,546						
						CAPEX	(229)	(778)	(720)	(740)	(750)
S&M expenses	(33)	(30)	(59)	(74)	(88)	Others	(54)	(108)	(83)	(81)	(79)
G&A expenses	(136)	(200)	(355)	(427)	(509)	Investing cash flow	(283)	(886)	(803)	(821)	(829)
R&D expenses	(227)	(354)	(769)	(958)	(1,140)						
Other opex	(39)	(70)	(119)	(149)	(163)	Proceeds from fund raising	18	265	-	-	-
Core operating profit	959	1,715	3,121	3,870	4,646	Changes in borrowings	(44)	(4)	10	10	10
Impairment losses	(137)	(100)	(227)	(278)	(325)	Dividends paid	(132)	(174)	(360)	(534)	(655)
Other expenses and incomes	129	300	87	63	53	Others	(209)	(11)	(2)	(3)	(3)
						Financing cash flow	(366)	75	(352)	(527)	(648)
Pre-tax profit	992	1,984	3,101	3,803	4,537						
Income tax	(140)	(256)	(403)	(494)	(590)	Net change in cash	305	927	669	392	1,933
Minority interest	6	(17)	(27)	(33)	(39)	Cash at the beginning	542	847	1,783	2,451	2,843
Net profit	858	1,712	2,671	3,276	3,908	Forex change, net	0	9	-	-	-
						Less: restricted cash	88	82	-	-	-
						Cash at the end	847	1,783	2,451	2,843	4,777

Balance sheet Key ratios

YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E	YE 31 Dec	FY20A	FY21A	FY22E	FY23E	FY24E
Current assets	7,962	13,190	20,396	24,532	29,899	Revenue mix (%)					
Cash and restricted cash	938	1,867	2,536	2,927	4,861	Equipment and service	86	83	88	89	89
Trade receivables	3,713	4,147	10,292	12,521	14,563	Sapphire products	5	7	5	5	5
Inventories	2,580	6,051	6,443	7,958	9,349	Others	9	10	7	7	6
Other current assets	731	1,126	1,126	1,126	1,126						
						YoY growth (%)					
Non-current assets	2,536	3,694	4,355	4,996	5,602	Revenue	23	56	98	25	19
Long-term equity investment	824	977	1,102	1,230	1,362	Gross profit	26	70	87	24	20
Fixed assets	1,135	1,509	1,925	2,364	2,791	Net profit	35	99	56	23	19
Other non-current assets	577	1,208	1,327	1,402	1,449						
Total assets	10,498	16,884	24,751	29,528	35,500	Operating efficiency					
						Gross margin	36.6	39.7	37.4	37.2	37.3
Current liabilities	5,201	9,620	15,149	17,151	19,830	Core operating margin	25.2	28.8	26.4	26.3	26.5
ST borrowings	22	29	39	48	58	Net profit margin	22.5	28.7	22.6	22.2	22.3
Trade payables	2,775	4,147	8,443	9,254	10,449						
Contract liabilities	2,003	4,964	6,187	7,369	8,843	B/S ratios (%)					
Other current liabilities	401	480	480	480	480	Net gearing	Net cash				
						Receivable turnover	303	216	214	283	282
Non-current liabilities	46	147	148	148	149	Inventory turnover	190	264	193	178	180
LT borrowings	11	2	2	3	3	Payable turnover days	351	352	310	349	327
Other non-current liabilities	35	146	146	146	146						
Total liabilities	5,247	9,767	15,296	17,299	19,979	Profitability (%)					
						ROE	17.5	28.4	33.4	31.2	28.9
Share capital	1,286	1,286	1,286	1,286	1,286	ROA	9.3	12.5	12.8	12.1	12.0
Reserves	1,528	1,738	1,738	1,738	1,738						
Retained earnings	2,426	3,810	6,121	8,863	12,115	Per share data (RMB)					
Shareholders' fund	5,240	6,835	9,146	11,887	15,140	EPS	0.67	1.33	2.08	2.55	3.04
Minority interest	12	281	308	341	381	DPS	0.14	0.28	0.42	0.51	0.61
Total equity	5,251	7,116	9,454	12,229	15,521	BVPS	4.08	5.31	7.11	9.24	11.77

Source: Company data, CMBIGM estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY
Stock with potential return of over 15% over next 12 months
SELL
Stock with potential return of +15% to -10% over next 12 months
SELL
Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.